Cerity Partners
LXRX icon

Cerity Partners’s Lexicon Pharmaceuticals LXRX Stock Holding History

Cerity Partners’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$236K Sell
98,400
-12,058
-11% -$23.5K ﹤0.01% 2957
2026
Q1 		$172K Sell
110,458
-34,486
-24% -$50.1K ﹤0.01% 2918
2025
Q4 		$167K Sell
144,944
-13,096
-8% -$18K ﹤0.01% 2682
2025
Q3 		$213K Sell
158,040
-48,239
-23% -$54.7K ﹤0.01% 2472
2025
Q2 		$195K Buy
206,279
+35,892
+21% +$23.3K ﹤0.01% 2364
2025
Q1 		$78.5K Buy
170,387
+73,875
+77% +$46.6K ﹤0.01% 2354
2024
Q4 		$71.3K Buy
96,512
+74,000
+329% +$89.2K ﹤0.01% 2364
2024
Q3 		$35.3K Hold
22,512
– – ﹤0.01% 2498
2024
Q2 		$37.8K Hold
22,512
– – ﹤0.01% 2185
2024
Q1 		$54K Buy
+22,512
New +$48.4K ﹤0.01% 2244
2022
Q1 		– Sell
-73,000
Closed -$288K – 1039
2021
Q4 		$288K Buy
+73,000
New +$355K ﹤0.01% 782

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Cerity Partners's LXRX Position: Q2 2026 in Review

Cerity Partners reduced its Lexicon Pharmaceuticals (LXRX) stake by 11% in Q2 2026, selling an estimated $23.5K and leaving 98,400 shares worth $236K. The position accounts for ﹤0.01% of the portfolio, ranked #2957.

Cerity Partners first reported a position in LXRX in Q4 2021 and has held it in 11 quarters since. The position peaked at $288K in Q4 2021. 149 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • Cerity Partners held 98,400 shares of Lexicon Pharmaceuticals worth $236K as of Q2 2026.
  • Cerity Partners sold 12,058 Lexicon Pharmaceuticals shares in Q2 2026, an estimated $23.5K.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #2957 holding.
  • Cerity Partners first reported a position in Lexicon Pharmaceuticals in Q4 2021 and has held it in 11 quarters since.
  • Cerity Partners's Lexicon Pharmaceuticals position peaked at $288K in Q4 2021.
  • 149 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.